

This article was downloaded by:

On: 27 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

Inhibition of Human Immunodeficiency Virus (HIV) Production by 5'-Hydrogenphosphonates of 3'-Azido-2',3'- dideoxynucleosides

Natalya B. Tarussqva^a; Marina K. Kukhanova^a; Alexander A. Krayevsky^a; Edward K. Karamov^b; Vladimir V. Lukashov^b; Galina B. Kornilayeva^b; Mariana A. Rodina^b; Georgii A. Galecov^b

^a V. Engelhardt Institute of Molecular Biology, the USSR Academy of Sciences, Moscow, USSR ^b Ivanovskii Institute of Virology, the USSR Academy of Medical Sciences, Moscow, USSR

To cite this Article Tarussqva, Natalya B. , Kukhanova, Marina K. , Krayevsky, Alexander A. , Karamov, Edward K. , Lukashov, Vladimir V. , Kornilayeva, Galina B. , Rodina, Mariana A. and Galecov, Georgii A.(1991) 'Inhibition of Human Immunodeficiency Virus (HIV) Production by 5'-Hydrogenphosphonates of 3'-Azido-2',3'- dideoxynucleosides', *Nucleosides, Nucleotides and Nucleic Acids*, 10: 1, 351 — 354

To link to this Article: DOI: 10.1080/07328319108046477

URL: <http://dx.doi.org/10.1080/07328319108046477>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) PRODUCTION BY
5'-HYDROGENPHOSPHONATES OF 3'-AZIDO-2',3'-DIDEOXYNUCLEOSIDES

Natalya B.TARUSSOVA, Marina K.KUKHANOVA, Alexander A.KRAYEVSKY,
Edward K.KAROMOV, Vladimir V.LUKASHOV, Galina B.KORNILAYEVA,
Mariana A.RODINA, Georgii A.GALEGOV

V.Engelhardt Institute of Molecular Biology, the USSR Academy of
Sciences, Vavilov str.32, Moscow 117984, USSR; D.Ivanovskii
Institute of Virology, the USSR Academy of Medical Sciences,
Gamaleya str.16, Moscow 123098, USSR

ABSTRACT. 3'-Azido-2',3'-dideoxynucleoside 5'-hydrogenphos-
phonates with thymine, adenine, guanine and cytosine bases inhi-
bit HIV-1 reproduction in MT4 cell cultures. The most active was
5'-hydrogenphosphonate of 3'-azido-2',3'-dideoxythymidine. Equi-
molar mixture of all four hydrogenphosphonates is shown to be
less toxic in comparison with each of compounds taken separately.

Among 3'-azido-2',3'-dideoxynucleosides a high anti-HIV
activity has been found for 3'-azido-2',3'-dideoxythymidine
(AZT), whereas 3'-azido-2',3'-dideoxynucleosides with adenine
(AZA), guanine (AZG) and cytosine (AZC) bases are shown to be
less active [1,2]. The reasons for such difference in activity
depend mainly on poor phosphorylation of the latter three
compounds into their 5'-triphosphates in cells as compared with
AZT. At the same time 5'-triphosphates of all 3'-azido-2',3'-
dideoxynucleosides blocked viral reverse transcriptases
activity in nearly the same degree [3,4].

The main toxic effect of AZT on human is connected with bone
marrow supression [5]. It probably occurs due to AZT dependent
disbalance of natural pool of 2'-deoxynucleoside triphosphates


Table 1. Anti-HIV activity and cytotoxicity of hydrogenphosphonates I-IV

Compound	ED ₅₀ , μ M	CD ₅₀ , μ M	SI
AZT	0.06	72	1200
I	0.03	102	3400
II	0.3	104	347
III	0.9	140	156
IV	>1	104	<104
mixture I-IV	0.09	250	2778

ED₅₀ - fifty percent effective dose, decreasing reverse transcriptase activity by 50%; CD₅₀ - fifty percent cytotoxic dose, based on the reduction of the viability of noninfected cells. SI - selectivity index - ratio CD₅₀ to ED₅₀.

in cells [6]; this disbalance induces depression of DNA replication in proliferating cells [7].

As it was reported by us earlier, three types of 5'-phosphonates of 3'-azido-2',3'-dideoxynucleosides [8,9] and some other modified nucleosides [10] blocked effectively the production of HIV-1 in cell cultures. These investigations were continued in the HIV-1 infected MT4 cells.



Synthesis of I-IV was made as in [8,9]. The action of phosphonates I-IV on HIV reproduction was evaluated on the 4th and 7th day of incubation by measuring reverse transcriptase activity, immunoenzyme analysis [8], reclustering method [10] and counting alive cells.

Table 1 shows that all four phosphonates I-IV block the HIV-1 reproduction, the selectivity index of I-IV as a rule is higher than that of the corresponding nucleosides. It should be noted specially that the toxicity of the I-IV mixture was 2-3 fold lower as compared with that for phosphonates I-IV separately. We believe that this fact can be interpreted as decreasing of the disbalance of the natural 2'-deoxynucleoside 5'-triphosphate pool in cells.

Table 2. Protection of HIV-infected cells with phosphonates I-IV by reclustering method and cytotoxic effect of I-IV on noninfected cells

Compound and its concentration, μM	Clusters formation* after incubation during		Survival cells after 7 days incubation with substances %
	4 days	7 days	
AZT 1	+++	-	71
10	++	-	73
I 1	+++	+-	80
10	+++	+-	75
II 1	++	-	72
10	++	-	70
III 1	+++	-	69
10	+++	-	68
IV 1	+-	-	68
10	++	-	69
mixture I-IV 0.25 each	+++	+	72
2.5	+++	+	81
-	-	-	19
mock-infected cells (control)	+++	+++	96

* - no clusters; +- a few clusters contain less than 20 cells in each; + clusters contain more than 20 cells; ++ clusters contain more than 60 cells; +++ all the cells in clusters

Table 3. Anti-HIV-1 activity of AZT and I

Substances	ED ₅₀ , μM	CD ₅₀ , μM	SI	Cell culture	Reference
AZT	0.005	210	30800	MT-4	[11]
	0.0139*	154	11079*		
I	0.072	2500	34700	A301	J.A.H.Verheiden Personal communication
	0.2763*	2500	9050*		
AZT	0.02	>200			
I	0.017	>200			

All designations as in Table 1. Activity of substances was tested by immunoenzyme analysis and reverse transcriptase test.

Analysis of the above mentioned data shows that all hydrogenphosphonates inhibit the HIV reproduction in MT4 cells and the equimolar mixture of I-IV is less toxic as compared with each of I-IV taken separately.

According to the immunoenzyme analysis the activity of the I-IV mixture was higher as compared with each of I-IV (data not shown).

Table 2 demonstrates the results of determination of the I-IV activity by reclustering method. Clusters of infected cells during incubation with virus dissociated. Each compound I-IV protected clusters due to HIV reproduction inhibition. As one can see from Table 2, after 4 days of incubation AZT and I-IV protected cell clusters comparatively well, but after 7 days incubation a minor protection was registered only for I. In contrast, the mixture of I-IV protects more than 20% of cells in clusters. This fact illustrates higher efficiency of the I-IV mixture as compared with I-IV taken separately.

Activity of I synthesised by us was tested in some other laboratories. Table 3 summerizes these data.

REFERENCES

1. P.Herdewijn, J.Balzarini, N.Baba, R.Pauwels, A.Van Aerschot, G.Janssen, E.DeClercq, J.Med.Chem. 31, 2040-2048 (1988).
2. E.DeClercq, A.Van Aerschot, P.Herdewijn, N.Baba, R.Pauwels, J.Balzarini, Nucleosides & Nucleotides (5+6), 659-674 (1989).
3. Z.G.Chidgeavadze, R.Sh.Beabealashvilli, A.A.Krayevsky, M.K.Kukhanova, Biochim.Biophys.Acta 868, 145-152 (1986).
4. A.A.Krayevsky, M.K.Kukhanova, Sov.Sci.Rev.Biol.Chem. 13, 3-69 (1989).
5. R.Yarchoan, H.Mitsuya, C.E.Myers, S.Broder, New England J.Med. 232, 726-738 (1989).
6. P.A.Furman, J.A.Fyfe, M.H.St.Clair, K.Weinhold, J.L.Rideout, G.A.Freeman, S.Nusinoff-Lehrman, D.P.Bolognesi, S.Broder, Proc.Natl.Acad.Sci.USA 83, 8333-8337 (1986).
7. K.L.Skoog, Bo A.Nordenskjold, K.G.Bjursell, Eur.J.Biochem. 33, 428-432 (1973).
8. A.A.Khorlin, N.B.Tarussova, N.B.Dyatkina, A.A.Krayevsky, R.Sh.Beabealashvilli, G.A.Galegov, V.M.Zhdanov, M.N.Korneyeva, D.N.Nosik, V.M.Shobukkhov, European Patent, Invention PCT/SU 88/0027, N89901341.1, priority from 29.12.1987.
9. N.B.Tarussova, A.A.Khorlin, A.A.Krayevsky, M.N.Korneyeva, D.N.Nosik, I.V.Kruglov, G.A.Galegov, R.Sh.Beabealashvilli, Mol.Biol., Moscow 23, 1716-1724 (1989).
10. G.Szucf, J.L.Melnick, F.B.Holvinger, Bull.World Health.Orga-nization 6 6, 729-737 (1988).
11. Q.-Y.Zhu, K.A.Watanabe, A.A.Krayevsky, N.B.Tarussova, B.W.Polsky, J.W.H.Gold, P.Baron, W.Hardy, D.Armstrong, T.-C.Chou, VI International AIDS Conference, Thesises Th.A.270, P.187 (1990).